Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Foghorn Therapeutics Inc
(NQ:
FHTX
)
5.900
-0.140 (-2.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Foghorn Therapeutics Inc
< Previous
1
2
3
4
Next >
Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
June 29, 2023
Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ: MU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market...
Via
Benzinga
Analyst Ratings for Foghorn Therapeutics
June 28, 2023
Via
Benzinga
Foghorn Therapeutics Shifts Focus from Development Of Cancer Hopeful with Eye Cancer
June 28, 2023
Foghorn Therapeutics Inc (NASDAQ: FHTX) announced the data from the Phase 1 dose escalation safety study of FHD-286 in
Via
Benzinga
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
June 28, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
What 6 Analyst Ratings Have To Say About Foghorn Therapeutics
June 08, 2023
Via
Benzinga
Analyst Expectations for Foghorn Therapeutics's Future
April 25, 2023
Via
Benzinga
Expert Ratings for Foghorn Therapeutics
March 28, 2023
Via
Benzinga
Foghorn Therapeutics Earnings Perspective: Return On Capital Employed
March 15, 2023
Via
Benzinga
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
June 07, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
June 05, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
May 08, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
April 25, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Crude Oil Up 1.5%; Philips Shares Jump After Q1 Results
April 24, 2023
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 40 points on Monday. The Dow traded up 0.05% to 33,827.42 while the NASDAQ fell 0.33% to 12,032.16....
Via
Benzinga
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 24, 2023
Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment.
Via
Benzinga
US Stocks Turn Lower; Nasdaq Dips 100 Points
April 24, 2023
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday. The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P...
Via
Benzinga
More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Hold
April 24, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 24, 2023
Via
Benzinga
Foghorn Therapeutics Provides an Update on FHD-609
April 24, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual
April 10, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
April 06, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
March 28, 2023
Via
Benzinga
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
March 09, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
March 01, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
February 16, 2023
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.
Via
The Motley Fool
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
January 09, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
December 05, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
November 30, 2022
During Wednesday's session, 107 stocks hit new 52-week lows.
Via
Benzinga
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
November 22, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
November 14, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.